If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Concomitant Use With an Insulin Secretagogue or With Insulin
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
insulin secretagogues, such as sulfonylureas, or
Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs
Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally coadministered medications.1
Caution should be exercised when oral medications are concomitantly administered with dulaglutide.1
Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with dulaglutide.1
In clinical pharmacology studies, treatment with dulaglutide did not affect, to any clinically relevant degree, the absorption of coadministered oral medications that included
No dose adjustment is recommended for any of these evaluated coadministered medications.1
Enclosed Prescribing Information
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Date of Last Review: July 10, 2018